Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Novartis AG ADR Stock

Price
Target price
€109.50

€109.50

-0.450%
-0.5
-0.450%
€100.61
 
07.11.25 / Tradegate WKN: 907122 / Symbol: NVS / Name: Novartis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Novartis AG ADR in the next few years
Wizard

Novartis AG ADR Stock

The price for the Novartis AG ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.450%).
With 5 Buy predictions and 4 Sell predictions the community is currently undecided on Novartis AG ADR.
On the other hand, the target price of 100 € is below the current price of 109.5 € for Novartis AG ADR, so the potential is actually -8.68%.
So far the community has only identified positive things for Novartis AG ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
What does Novartis do?

Pros and Cons of Novartis AG ADR in the next few years

Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Novartis AG ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novartis AG ADR -0.450% 1.860% -3.097% 10.383% 15.996% 34.191% 53.147%
Roche Holding AG ADR 1.450% 3.678% -6.362% 2.682% 9.025% -10.943% -2.400%
Bayer AG ADR 0.790% 0.000% -9.220% 12.281% 29.032% -52.239% -39.623%
Astrazeneca ADR 0.680% 2.083% -0.676% 22.500% 14.844% 20.492% 57.051%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.

Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.

Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.

Show more

Comments

Prediction Sell
Perf. (%) 2.82%
Target price 100.607
Change
Ends at 12.09.26

Novartis (NYSE:NVS) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $118.00 price target on the stock, down previously from $119.00.
Ratings data for NVS provided by MarketBeat
Show more

The Goldman Sachs Group, Inc. 
0
Report Share
12.09.25

Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Ratings data for NVS provided by MarketBeat
Show more

Deutsche Bank Aktiengesellschaft 
0
Report Share
26.08.25 Buy 0.46%

Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
Ratings data for NVS provided by MarketBeat
Show more

BNP Paribas 
0
Report Share
17.04.25 Buy 12.42%
Show more
Not a member yet? Sign up for free!

News

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think): https://g.foolcdn.com/editorial/images/840589/buy-hold-or-sell-a-stock.jpg
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per

TheMotleyFool 
0 31.10.25
Why Dyne Therapeutics Stock Crushed the Market on Monday: https://g.foolcdn.com/editorial/images/839953/person-in-a-lab-gazing-into-a-microscope.jpg
Why Dyne Therapeutics Stock Crushed the Market on Monday

Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, however, as a premium-priced buyout of a peer was attracting serious

TheMotleyFool 
0 27.10.25
Why Avidity Biosciences Stock Blasted 42% Higher Today: https://g.foolcdn.com/editorial/images/839946/person-checking-medicine-on-a-shelf-in-a-pharmacy.jpg
Why Avidity Biosciences Stock Blasted 42% Higher Today

A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below

TheMotleyFool 
0 27.10.25